# Inflammatory Bowel Disease

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/inflammatory-bowel-disease/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers explores the genetics, epidemiology, pathogenesis, and treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. It covers topics such as host-microbe interactions, genetic susceptibility loci, immune system involvement, therapeutic targets, and the global burden of these diseases. |
| Domain | Life Sciences |
| Field | Biochemistry, Genetics and Molecular Biology |
| OpenAlex ID | t10134 |
| Works | 725 |

## Topic papers all

Showing 15 of 725.

- [Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies](https://scholariq.org/papers/worldwide-incidence-and-prevalence-of-inflammatory-bowel-disease-in-the-21st/)
- [Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease](https://scholariq.org/papers/host-microbe-interactions-have-shaped-the-genetic-architecture-of-inflammatory/)
- [Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology](https://scholariq.org/papers/toward-an-integrated-clinical-molecular-and-serological-classification-of/)
- [A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene](https://scholariq.org/papers/a-genome-wide-association-study-identifies-i-il23r-i-as-an-inflammatory-bowel/)
- [Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/vedolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations](https://scholariq.org/papers/association-analyses-identify-38-susceptibility-loci-for-inflammatory-bowel/)
- [STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD](https://scholariq.org/papers/stride-ii-an-update-on-the-selecting-therapeutic-targets-in-inflammatory-bowel/)
- [Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease](https://scholariq.org/papers/genome-wide-association-defines-more-than-30-distinct-susceptibility-loci-for/)
- [Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci](https://scholariq.org/papers/genome-wide-meta-analysis-increases-to-71-the-number-of-confirmed-crohn-s/)
- [Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study](https://scholariq.org/papers/worldwide-prevalence-and-burden-of-functional-gastrointestinal-disorders-results/)
- [Burden of Gastrointestinal Disease in the United States: 2012 Update](https://scholariq.org/papers/burden-of-gastrointestinal-disease-in-the-united-states-2012-update/)
- [Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease](https://scholariq.org/papers/influence-of-immunogenicity-on-the-long-term-efficacy-of-infliximab-in-crohn-s/)
- [A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis](https://scholariq.org/papers/a-decrease-of-the-butyrate-producing-species-i-roseburia-hominis-i-and-i/)
- [Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders](https://scholariq.org/papers/third-european-evidence-based-consensus-on-diagnosis-and-management-of/)
- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)

## Topic primary papers

Showing 15 of 445.

- [Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies](https://scholariq.org/papers/worldwide-incidence-and-prevalence-of-inflammatory-bowel-disease-in-the-21st/)
- [Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease](https://scholariq.org/papers/host-microbe-interactions-have-shaped-the-genetic-architecture-of-inflammatory/)
- [Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology](https://scholariq.org/papers/toward-an-integrated-clinical-molecular-and-serological-classification-of/)
- [Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/vedolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations](https://scholariq.org/papers/association-analyses-identify-38-susceptibility-loci-for-inflammatory-bowel/)
- [STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD](https://scholariq.org/papers/stride-ii-an-update-on-the-selecting-therapeutic-targets-in-inflammatory-bowel/)
- [Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease](https://scholariq.org/papers/genome-wide-association-defines-more-than-30-distinct-susceptibility-loci-for/)
- [Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci](https://scholariq.org/papers/genome-wide-meta-analysis-increases-to-71-the-number-of-confirmed-crohn-s/)
- [Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease](https://scholariq.org/papers/influence-of-immunogenicity-on-the-long-term-efficacy-of-infliximab-in-crohn-s/)
- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease/)
- [Ulcerative Colitis and Colorectal Cancer](https://scholariq.org/papers/ulcerative-colitis-and-colorectal-cancer/)
- [Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/tofacitinib-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Ulcerative colitis](https://scholariq.org/papers/ulcerative-colitis-2/)
- [Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management](https://scholariq.org/papers/second-european-evidence-based-consensus-on-the-diagnosis-and-management-of/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.